Journal of Shandong University (Health Sciences) ›› 2025, Vol. 63 ›› Issue (9): 77-83.doi: 10.6040/j.issn.1671-7554.0.2025.0019
• Review • Previous Articles
LI Xiping1, QIU Mei2, HUANG Ruifeng2, LIN Huihui2, LIU Sisi2, LUO Hongying2, WANG Yuyue2, WANG Min2, YANG Xiaotong3
CLC Number:
| [1] 吴虹, 张正铎, 唐延金, 等. 5-甲基四氢叶酸对大鼠动脉粥样硬化的潜在干预作用[J]. 山东大学学报(医学版), 2022, 60(8): 6-13. WU Hong, ZHANG Zhengduo, TANG Yanjin, et al. Potential intervention effects of 5-methyltetrahydrofolate on atherosclerosis in rats[J]. Journal of Shandong University(Health Sciences), 2022, 60(8): 6-13. [2] Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis[J]. Nature, 2011, 473(7347): 317-325. [3] Liu HX, Zhang YC, Zhao YY, et al. Research progress and clinical translation potential of coronary atherosclerosis diagnostic markers from a genomic perspective[J]. Genes(Basel), 2025, 16(1): 98. doi: 10.3390/genes16010098 [4] Xia Y, Liu H, Zhu R, et al. Analysis of non-cardiogenic young minor ischemic stroke patients risk factors in Chinese Han population[J]. Med Sci Monit, 2025, 31: e946146. doi: 10.12659/MSM.946146 [5] Masoumi-Ardakani Y, Eghbalian M, Fallah H, et al. Exploring serum miR-33b as a novel diagnostic marker for hypercholesterolemia and obesity: insights from a pilot case-control study[J]. BMC Endocr Disord, 2025, 25(1): 27. doi: 10.1186/s12902-025-01849-9 [6] Nehaoua A, Gasmi A, Benahmed AG, et al. Lipid biochemistry and its role in human diseases[J]. Curr Med Chem, 2025. doi: 10.2174/0109298673351452241220071215 [7] Gong ZH, Yang HX, Gao L, et al. Mechanisms of wogonoside in the treatment of atherosclerosis based on network pharmacology, molecular docking, and experimental validation[J]. BMC Complement Med Ther, 2025, 25(1): 28. doi: 10.1186/s12906-025-04760-x [8] Shi Z, Huang J, Chen C, et al. Lipid nanoparticles encapsulating curcumin for imaging and stabilization of vulnerable atherosclerotic plaques via phagocytic “eat-me” signals[J]. J Control Release, 2024, 373: 265-276. doi: 10.1016/j.jconrel.2024.07.027 [9] Yang AN, Zhang HW, Zhang HP, et al. Pitavastatin and resveratrol bio-nano complexes against hyperhomocysteinemia-induced atherosclerosis via blocking ferroptosis-related lipid deposition[J]. J Control Release, 2025, 381: 113598. doi: 10.1016/j.jconrel.2025.113598 [10] Zhang LH, Wang HX, Wang ZS, et al. Resveratrol promotes cholesterol efflux from dendritic cells and controls costimulation and T-cell activation in high-fat and lipopolysaccharide-driven atherosclerotic mice[J]. Front Cardiovasc Med, 2024, 11: 1450898. doi: 10.3389/fcvm.2024.1450898 [11] Du JD, Zhu Y, Yang XH, et al. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion[J]. Diabet Med, 2024, 41(7): e15319. doi: 10.1111/dme.15319 [12] Ming Y, He XY, Zhao ZX, et al. Nanocarrier-assisted delivery of berberine promotes diabetic alveolar bone regeneration by scavenging ROS and improving mitochondrial dysfunction[J]. Int J Nanomedicine, 2024, 19: 10263-10282. doi: 10.2147/IJN.S475320 [13] Wei GL, Huang N, Li MY, et al. Tetrahydroberberine alleviates high-fat diet-induced hyperlipidemia in mice via augmenting lipoprotein assembly-induced clearance of low-density lipoprotein and intermediate-density lipoprotein[J]. Eur J Pharmacol, 2024, 968: 176433. doi: 10.1016/j.ejphar.2024.176433 [14] Wang KX, Li ZX, Zhang WC, et al. The study on synthesis and vitro hypolipidemic activity of novel berberine derivatives nitric oxide donors[J]. Fitoterapia, 2024, 176: 105964. doi: 10.1016/j.fitote.2024.105964 [15] Ding LN, Xia JJ, Wang H, et al. Berberine improves glucose and lipid metabolism in obese mice through the reduction of IRE1/GSK-3β axis-mediated inflammation[J]. Endocr Metab Immune Disord Drug Targets, 2025. doi: 10.2174/0118715303319434241113161606 [16] Kong Y, Yi YJ, Liu XQ, et al. Discovery and structural optimization of 9-O-phenylsulfonyl-berberines as new lipid-lowering agents[J]. Bioorg Chem, 2022, 121: 105665. doi: 10.1016/j.bioorg.2022.105665 [17] Zhao Y, Yang YY, Yang BL, et al. Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial[J]. Trials, 2021, 22(1): 85. doi: 10.1186/s13063-021-05028-8 [18] Wu CM, Zhao Y, Zhang YY, et al. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine(BBR)and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients[J]. J Adv Res, 2021, 37: 197-208. doi: 10.1016/j.jare.2021.07.011 [19] Hu WH, Feng H, Liu Y, et al. Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention[J]. Hum Vaccin Immunother, 2025, 21(1): 2462466. doi: 10.1080/21645515.2025.2462466 [20] Winnie Ho TW, Wang C, Lee WL. LDL transcytosis passes through the trans-Golgi network and requires Rab10[J]. J Lipid Res, 2025:100893. doi: 10.1016/j.jlr.2025.100893 [21] Borén J, Taskinen MR, Packard CJ. Biosynthesis and metabolism of ApoB-containing lipoproteins[J]. Annu Rev Nutr, 2024, 44(1): 179-204. [22] Matsuo M, Takaoka S, Nakayama K, et al. Fatty acids from cheese stimulate cholesterol efflux by ATP-binding cassette transporters[J]. Biosci Biotechnol Biochem, 2025, 89(4): 573-585. [23] Liao WQ, Li Y, Zhao HY, et al. The Lian-Dou-Qing-Mai Formula activates the PPARγ-LXRα-ABCA1/ABCG1 pathway by regulating IL-10, leading to the promotion of cholesterol efflux and a reduction in atherosclerotic plaques[J]. Histol Histopathol, 2025, 40(4): 585-596. [24] Zhang ST, Du JJ, Wang P, et al. Association between estimated small dense low-density lipoprotein-cholesterol(sdLDL-C)and atherosclerotic cardiovascular disease risk[J]. Arq Bras Cardiol, 2025, 122(1): e20240265. doi: 10.36660/abc.20240265 [25] Zhang SX, Sun L, Xu XY, et al. Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis[J]. BMC Cardiovasc Disord, 2024, 24(1): 629. doi: 10.1186/s12872-024-04321-z [26] Ginsberg HN, Packard CJ, Chapman MJ, et al. Trigly-ceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society[J]. Eur Heart J, 2021, 42(47): 4791-4806. [27] Khoury E, Lauzière A, Raal FJ, et al. Atherosclerotic plaque regression in homozygous familial hypercholestero-laemia: a case report of a long-term lipid-lowering the-rapy involving LDL-receptor-independent mechanisms[J]. Eur Heart J Case Rep, 2023, 7(1): ytad029. doi: 10.1093/ehjcr/ytad029 [28] Dai W, Zhang H, Lund H, et al. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes[J]. Science, 2023, 381(6661): eadh5207. doi: 10.1126/science.adh5207 [29] Munkhsaikhan U, Ait-Aissa K, Sahyoun AM, et al. Lomitapide: navigating cardiovascular challenges with innovative therapies[J]. Mol Biol Rep, 2024, 51(1): 1082. doi: 10.1007/s11033-024-10003-y [30] Goldstein JL, Brown MS. The LDL receptor and the regulation of cellular cholesterol metabolism[J]. J Cell Sci Suppl, 1985, 3: 131-137. doi: 10.1242/jcs.1985.supplement_3.13 [31] Rosenson RS, Jr HBB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport[J]. Circulation, 2012, 125(15): 1905-1919. [32] Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice[J]. J Clin Invest, 2000, 105(8): 1049-1056. [33] Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers[J]. Circ Res, 2015, 116(2): 307-311. [34] Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders[J]. Nature, 2017, 542(7640): 177-185. [35] Zhou X, Ren FY, Wei H, et al. Combination of ber-berine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats[J]. Lipids Health Dis, 2017, 16(1): 239. doi: 10.1186/s12944-017-0628-x [36] Cai YJ, Yang QN, Yu YQ, et al. Efficacy and underl-ying mechanisms of berberine against lipid metabolic diseases: a review[J]. Front Pharmacol, 2023, 14: 1283784. doi: 10.3389/fphar.2023.1283784 [37] Cao SJ, Zhou Y, Xu PX, et al. Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells[J]. J Ethnopharmacol, 2013, 149(2): 576-582. [38] Alruhaimi RS, Siddiq Abduh M, Ahmeda AF, et al. Berberine attenuates inflammation and oxidative stress and modulates lymphocyte E-NTPDase in acute hyperlipidemia[J]. Drug Dev Res, 2024, 85(2): e22166. doi: 10.1002/ddr.22166 [39] Chen C, Liu XC, Deng B. Protective effects of berberine on nonalcoholic fatty liver disease in db/db mice via AMPK/SIRT1 pathway activation[J]. Curr Med Sci, 2024, 44(5): 902-911. [40] Feng J, Xu R, Dou ZJ, et al. Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK/SREBP2/PCSK9/LDL receptor signaling pathway[J]. Eur J Pharmacol, 2025, 989: 177228. doi: 10.1016/j.ejphar.2024.177228 [41] Cicero AFG, Fogacci F, Stoian AP, et al. Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels?[J]. Curr Atheroscler Rep, 2021, 23(10): 57. doi: 10.1007/s11883-021-00955-y [42] Tian Y, Cai JW, Gui W, et al. Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor activation[J]. Drug Metab Dispos, 2019, 47(2): 86-93. [43] Wang C, Yang YT, Chen JY, et al. Berberine protects against high-energy and low-protein diet-induced hepatic steatosis: modulation of gut microbiota and bile acid metabolism in laying hens[J]. Int J Mol Sci, 2023, 24(24): 17304. doi: 10.3390/ijms242417304 [44] Yang XJ, Liu F, Feng N, et al. Berberine attenuates cholesterol accumulation in macrophage foam cells by suppressing AP-1 activity and activation of the Nrf2/HO-1 pathway[J]. J Cardiovasc Pharmacol, 2020, 75(1): 45-53. [45] Song T, Chen WD. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway[J]. Bioengineered, 2021, 12(1): 8135-8146. [46] Wang TT, Yu LL, Zheng JM, et al. Berberine inhibits ferroptosis and stabilizes atherosclerotic plaque through NRF2/SLC7A11/GPX4 pathway[J]. Chin J Integr Med, 2024, 30(10): 906-916. [47] Ma SR, Tong Q, Lin Y, et al. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota[J]. Signal Transduct Target Ther, 2022, 7(1): 207. doi: 10.1038/s41392-022-01027-6 [48] Ma CY, Shi XY, Wu YR, et al. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway[J]. Ann Transl Med, 2021, 9(20): 1517. doi: 10.21037/atm-20-8106 [49] Fatahian A, Haftcheshmeh SM, Azhdari S, et al. Promising anti-atherosclerotic effect of berberine: evidence from in vitro, in vivo, and clinical studies[J]. Rev Physiol Biochem Pharmacol, 2020, 178: 83-110. doi: 10.1007/112_2020_42 [50] Yang LL, Zhu WY, Zhang XB, et al. Efficacy and safety of berberine for several cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials[J]. Phytomedicine, 2023, 112: 154716. doi: 10.1016/j.phymed.2023.154716 [51] Sharma S, Sharma D, Dhobi M, et al. An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α[J]. Mol Cell Biochem, 2024, 479(3): 707-732. [52] Wu M, Yang SJ, Wang SZ, et al. Effect of berberine on atherosclerosis and gut microbiota modulation and their correlation in high-fat diet-fed ApoE-/- mice[J]. Front Pharmacol, 2020, 11: 223. doi: 10.3389/fphar.2020.00223 [53] Wu SN, Zou MH. AMPK, mitochondrial function, and cardiovascular disease[J]. Int J Mol Sci, 2020, 21(14): 4987. doi: 10.3390/ijms21144987 [54] Yu MY, Alimujiang M, Hu LL, et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver[J]. Int J Biol Sci, 2021, 17(7): 1693-1707. [55] Ilyas Z, Perna S, Al-Thawadi S, et al. The effect of berberine on weight loss in order to prevent obesity: a systematic review[J]. Biomed Pharmacother, 2020, 127: 110137. doi: 10.1016/j.biopha.2020.110137 [56] Cicero AFG, Fogacci F, Tocci G, et al. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus® and placebo[J]. Arch Med Sci, 2023, 19(5): 1169-1179. |
| [1] | DU Aijia, ZHANG Man, CHEN He, WANG Lixin, SHANG Yingshu. miR-1270-targeted regulation of angiopoietin-like protein 7 inhibits macrophage inflammation and lipid accumulation [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 1-9. |
| [2] | WU Tong, YANG Jingyu, LIN Dang, XU Wanru, ZENG Yujun. Genetic association of lipids and lipid-lowering drugs with chronic obstructive pulmonary disease based on Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 54-63. |
| [3] | ZHAO Zhibo, MAN Zhentao, LI Wei. Role of cholesterol metabolism in osteoarthritis: a review of research progresses [J]. Journal of Shandong University (Health Sciences), 2024, 62(2): 1-9. |
| [4] | XU Tianqi, CHANG Na, ZHANG Shuai, LI Sha, JIAO Bingxuan, YU Xinxin, WANG Ximing. Identification of carotid high-risk plaques by non-alcoholic fatty liver disease based on CTA [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 36-43. |
| [5] | WU Hong, ZHANG Zhengduo, TANG Yanjin, QI Shaojun, GAO Xibao. Potential intervention effects of 5-methyltetrahydrofolate on atherosclerosis in rats [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 6-13. |
| [6] | ZHAO Meiru, ZHU Di, LIU Lin, GUAN Qingbo, ZHANG Xu. Association of 4 simple insulin resistance indicators with the risk of hyperuricemia in 698 patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 44-51. |
| [7] | XIE Jiaying, QI Jia, SONG Ming, LI Yulin, WANG Di, JIA Xu, ZHANG Wei, ZHONG Ming, SHANG Yuanyuan. Association between serum β-sheet level and coronary heart disease [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 21-26. |
| [8] | ZHANG Ludan, DING Xiaoling, CUI Shuyue, CHENG Chen, WEI Fulan, DING Gang. Periodontal ligament stem cells regulate the functions of macrophages in vitro [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 35-40. |
| [9] | JIANG Yong, SONG Jiangang, ZHU Daxia, LIU Lijian. Effects of naringenin on acute lung injury induced by sepsis via regulating the activation of NLRP3 inflammasome in macrophages [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 14-21. |
| [10] | FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24-31. |
| [11] | XU Yuxiang, LIU Yudong, ZHANG Peng, DUAN Ruisheng. A retrospective analysis of risk factors of cerebral microbleeds in 101 patients with cerebral small vessel disease [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 67-71. |
| [12] | LI Yan, SUN Fengjiao, ZHANG Tianran, WANG Yuxin, ZHANG Zhengduo, GAO Xibao. Effects of high-sugar, high-fat diet and different concentrations of selenium on lipid metabolism and oxidative stress in rats [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 98-106. |
| [13] | ZHANG Xiaolu, WANG Lili, CHEN Kaiming, LOU Xianzhi, ZHANG Man. Mechanism of histone deacetylase SIRT1 inhibiting macrophages apoptosis via TLR4 signaling pathway [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 8-14. |
| [14] | LI Changda, SHI Yongjun, LIN Yanliang. Effects of 27-hydroxycholesterol and cholesterol on the proliferation of esophageal squamous cell carcinoma in nude mice and human esophageal carcinoma cells(ECA109) [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 45-52. |
| [15] | LI Mingzhuo, SUN Xiubin, WANG Chunxia, YANG Yang, LIU Xinhui, LIU Yanxun, XUE Fuzhong, YUAN Zhongshang. Association between longitudinal changes of HDL-C and coronary heart disease in a population with normal serum lipids: a retrospective cohort study [J]. Journal of Shandong University (Health Sciences), 2019, 57(8): 110-116. |
|
||
